Evidence map›Paper›PMID 29195510›Full record

ArticleActa neuropathologica communications2017

Cerebrovascular pathology in Down syndrome and Alzheimer disease.

Elizabeth Head, Michael J Phelan, Eric Doran, Ronald C Kim, Wayne W Poon, Frederick A Schmitt, Ira T Lott

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04735874 (Vascular Health and Risk Factors in Children With Down Syndrome), which is not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04735874 completednot on this mapstarted 2021, after this paper: background citation

Vascular Health and Risk Factors in Children With Down Syndrome

TypeobservationalSponsorUniversity of UtahRan2021 to 2023Enrolled55ConditionsDown Syndrome, Cardiovascular Risk Factor, AtherosclerosisArmsEvaluate vascular disease risk factors in children with Down Syndrome, Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Sex differences in cardiovascular disease and dysregulation in Down syndrome.American journal of physiology. Heart and circulatory physiology · 2023
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  8. Article
  9. Article
  10. Development of Molecular Neuropathology in Down Syndrome across the Lifespan.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Review
  11. Review
  12. Article
  13. Vertebrate and Invertebrate Animal Models for the Study of Down Syndrome.International journal of molecular sciences · 2025
    Review
  14. Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  15. Age and sex are associated with Alzheimer's disease neuropathology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  16. Leptin levels are associated with body mass index and Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Review
  18. Article
  19. Lipoprotein(a) levels in Down syndrome: A conundrum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elizabeth HeadUniversity of Kentucky, Sanders-Brown Center on Aging, 800 South Limestone Street, Lexington, KY, 40536, USA. elizabeth.head@uky.edu.
Michael J PhelanDepartment of Statistics, University of California, Irvine, Irvine, CA, USA.
Eric DoranDepartment of Pediatrics, University of California, Irvine, Irvine, CA, USA.
Ronald C KimDepartment of Pathology, University of California, Irvine, Irvine, CA, USA.
Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Frederick A SchmittUniversity of Kentucky, Sanders-Brown Center on Aging, 800 South Limestone Street, Lexington, KY, 40536, USA.
Ira T LottDepartment of Pediatrics, University of California, Irvine, Irvine, CA, USA.
University of California, Irvine · USUniversity of Kentucky · US

Funding

UC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0M
University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI GOLD, BRIAN TIMOTHY, VAN ELDIK, LINDA J · 2006 to 2020
$23.3M
Aging of Frontal Structure and Function in Down Syndrome and DementiaR01HD064993 · NICHD · UNIVERSITY OF KENTUCKY · PI HEAD, ELIZABETH, SCHMITT, FREDERICK · 2009 to 2019
$5.1M
Predicting Cognitive Decline in Adults with Down SyndromeR01HD065160 · NICHD · UNIVERSITY OF CALIFORNIA-IRVINE · PI LOTT, IRA T. · 2009 to 2013
$2.3M
Alzheimer's Disease in Down Syndrome: Antioxidant TrialR01AG021912 · NIA · UNIVERSITY OF CALIFORNIA IRVINE · PI LOTT, IRA T · 2003 to 2005
$1.1M
National Institute of Child Health and Human Development R01HD064993National Institute of Child Health and Human Development R01HD065160NIA NIH HHS P30 AG028383NIA NIH HHS P50 AG016573NIA NIH HHS P50AG16573NIA NIH HHS R01 AG021912NIA NIH HHS R01AG21912NICHD NIH HHS R01 HD064993NICHD NIH HHS R01 HD065160
6 · The paper itself

Abstract

People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age 40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and hypertension are atypical in DS with age, suggesting the lack of these vascular risk factors may be associated with reduced cerebrovascular pathology. However, because the extra copy of APP leads to increased beta-amyloid peptide (Aβ) accumulation in DS, we hypothesized that there would be more extensive and widespread cerebral amyloid angiopathy (CAA) with age in DS relative to sporadic AD. To test this hypothesis CAA, atherosclerosis and arteriolosclerosis were used as measures of cerebrovascular pathology and compared in post mortem tissue from individuals with DS (n = 32), sporadic AD (n = 80) and controls (n = 37). CAA was observed with significantly higher frequencies in brains of individuals with DS compared to sporadic AD and controls. Atherosclerosis and arteriolosclerosis were rare in the cases with DS. CAA in DS may be a target for future interventional clinical trials.

Indexed as

AgedAged, 80 and overAge FactorsAlzheimer DiseaseArteriolosclerosisAtherosclerosisCerebral Amyloid AngiopathyCohort StudiesDown SyndromeFemaleHumansMaleMiddle AgedProbabilityArteriolosclerosisAtherosclerosisCerebral amyloid angiopathyTrisomy 21Vascular risk factors

Identifiers

PMID29195510
PMCPMC5709935
OpenAlexW2771929031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.